$214 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 41 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 52.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $28,149,000 | +11.3% | 554,000 | +3.6% | 13.15% | +23.7% |
| AADI BIOSCIENCES INC | $25,954,000 | -29.7% | 1,529,402 | 0.0% | 12.13% | -21.9% | ||
| VTGN | VISTAGEN THERAPEUTICS INC | $14,553,000 | -36.4% | 11,736,283 | 0.0% | 6.80% | -29.3% | |
| CLDX | Sell | CELLDEX THERAPEUTICS INC | $10,998,000 | -16.3% | 322,898 | -5.1% | 5.14% | -7.0% |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $9,231,000 | +1.4% | 342,000 | -15.3% | 4.31% | +12.7% |
| ISEE | Buy | IVERIC BIO INC | $9,080,000 | +15.6% | 539,500 | +14.8% | 4.24% | +28.4% |
| BLSA | BCLS ACQUISITION CORP- CL A | $8,322,000 | +0.7% | 843,122 | 0.0% | 3.89% | +11.9% | |
| GHRS | GH RESEARCH PLCordinary shares | $7,675,000 | -21.6% | 419,632 | 0.0% | 3.59% | -12.9% | |
| KURA | Buy | KURA ONCOLOGY INC. COMMON STOCK | $7,621,000 | +86.5% | 473,969 | +62.4% | 3.56% | +107.4% |
| XENE | XENON PHARMACEUTICALS INC | $6,878,000 | -2.1% | 225,000 | 0.0% | 3.21% | +8.8% | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $6,287,000 | 0.0% | 340,000 | +6.9% | 2.94% | +11.1% |
| MRUS | MERUS NV | $6,227,000 | -16.9% | 235,500 | 0.0% | 2.91% | -7.6% | |
| BLU | Buy | BELLUS HEALTH INC | $5,614,000 | +32.8% | 816,000 | +55.4% | 2.62% | +47.7% |
| JYAC | JIYA ACQUISITION CORP -CL A | $5,524,000 | +0.5% | 562,500 | 0.0% | 2.58% | +11.7% | |
| JNCE | Buy | JOUNCE THERAPEUTICS INC | $5,524,000 | +418.7% | 813,500 | +538.0% | 2.58% | +476.1% |
| FULC | FULCRUM THERAPEUTICS INC | $4,730,000 | +33.7% | 200,000 | 0.0% | 2.21% | +48.6% | |
| MRTX | Buy | MIRATI THERAPEUTICS | $4,317,000 | +47.1% | 52,500 | +162.5% | 2.02% | +63.6% |
| AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $3,961,000 | – | 580,000 | +100.0% | 1.85% | – |
| HSAQ | HEALTH SCIENCES ACQUISITIONS | $3,890,000 | -1.7% | 392,500 | 0.0% | 1.82% | +9.3% | |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS INC | $3,794,000 | -45.8% | 82,500 | -21.8% | 1.77% | -39.7% |
| ACRS | Buy | ACLARIS THERAPEU | $3,751,000 | +163.2% | 217,600 | +122.0% | 1.75% | +192.7% |
| EYPT | Buy | EYEPOINT PHARMACEUTICALS INC | $3,742,000 | +25.8% | 307,944 | +26.7% | 1.75% | +39.8% |
| SNDX | SYNDAX PHARMACEUTICALS INC | $3,582,000 | -20.6% | 206,126 | 0.0% | 1.67% | -11.8% | |
| HZNP | New | HORIZON THERAPEUTICS PLC | $3,493,000 | – | 33,200 | +100.0% | 1.63% | – |
| PMVP | New | PMV PHARMACEUTICALS INC | $2,821,000 | – | 135,500 | +100.0% | 1.32% | – |
| HARP | New | HARPOON THERAPEUTICS INC | $2,473,000 | – | 497,500 | +100.0% | 1.16% | – |
| MIST | New | MILESTONE PHARMACEUTICALS IN | $2,440,000 | – | 380,000 | +100.0% | 1.14% | – |
| PMVP | New | CALL- PMVP 100 @ 20 EXP 06/17/2022call | $2,082,000 | – | 100,000 | +100.0% | 0.97% | – |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $1,979,000 | -42.4% | 118,856 | -34.0% | 0.92% | -35.9% |
| ATHA | Sell | ATHIRA PHARMA INC | $1,890,000 | -53.2% | 140,030 | -54.8% | 0.88% | -48.0% |
| VSTM | Sell | VERASTEM INC | $1,406,000 | -63.2% | 996,951 | -46.5% | 0.66% | -59.1% |
| ATHA | New | CALL- ATHA 100@12 1/2 EXP 07/15/2022call | $1,350,000 | – | 100,000 | +100.0% | 0.63% | – |
| MTEM | Sell | MOLECULAR TEMPLATES INC | $1,060,000 | -16.1% | 307,125 | -4.8% | 0.50% | -6.8% |
| New | VENTYX BIOSCIENCES INC | $962,000 | – | 70,877 | +100.0% | 0.45% | – | |
| Sell | PYXIS ONCOLOGY INC | $808,000 | -89.1% | 200,000 | -70.5% | 0.38% | -87.9% | |
| New | DICE THERAPEUTICS INC | $717,000 | – | 37,500 | +100.0% | 0.34% | – | |
| ACIU | New | CALL- ACIU 100@7 1/2EXP 08/19/2022call | $400,000 | – | 100,000 | +100.0% | 0.19% | – |
| IMGN | New | IMMUNOGEN INC | $262,000 | – | 55,000 | +100.0% | 0.12% | – |
| SEEL | Sell | SEELOS THERAPEUTICS INC | $248,000 | -93.9% | 295,896 | -88.2% | 0.12% | -93.2% |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $164,000 | – | 2,300 | +100.0% | 0.08% | – |
| NUVB | NUVATION WARRANTS*w exp 07/07/202 | $69,000 | -59.9% | 90,832 | 0.0% | 0.03% | -55.6% | |
| GRTX | Exit | GALERA THERAPEUTICS INC | $0 | – | -262,500 | -100.0% | -0.51% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -119,843 | -100.0% | -0.57% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -68,500 | -100.0% | -0.63% | – |
| ALDX | Exit | ALDEYRA THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -0.84% | – |
| ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -230,000 | -100.0% | -1.34% | – |
| CYT | Exit | CYTEIR THERAPEUTICS INC | $0 | – | -391,974 | -100.0% | -1.87% | – |
| Exit | AVADEL PHARMACEUTICALS PLCsponsored adr | $0 | – | -580,000 | -100.0% | -1.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.